Longitudinal analysis identifies disease progression in pediatric metabolic dysfunction, suggesting a need for better biomarkers.
Longitudinal VCTE in pediatric MASLD has the potential to identify disease progression. The intraindividual variability of CAP and LSM may limit the ability to detect short-term regression or progression, highlighting the need for more precise noninvasive biomarkers for pediatric MASLD.
No takes yet. Share an insight, caveat, or question.
Diop‐West et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: